The shares of GlaxoSmithKline ($GSK) cheered on Monday after the British pharmaceutical giant announced that its chief executive, Emma Walmsley, ...

The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

Dame Emma Walmsley will step down as GSK’s chief executive at the end of the year, concluding nine years at the helm of Britain’s second-largest pharmaceuticals company.

GSK named Luke Miels to succeed Emma Walmsley as the British drugmaker’s CEO. - chris j ratcliffe/Reuters GSK said Emma Walmsley would step down after more than eight years as chief executive and ...

Emma Walmsley, GSK's CEO, will be replaced by Luke Miels, the chief commercial officer, after almost nine years in the role. Miels has been with GSK since 2017 and has led global medicines and vaccine ...

We recently published 11 Stocks Crushing Wall Street With Whopping Gains. GSK plc (NYSE:GSK) is one of the top performers on Tuesday. Shares of GSK rallied for a third straight day on Tuesday to hit a ...

GSK's CEO Emma Walmsley will step down at the end of the year and be replaced by insider Luke Miels, the drugmaker said on Monday, a surprise switch as the British firm looks to rev up its pipeline ...

GSK chief executive Emma Walmsley is to step down after more than eight years running the pharmaceuticals giant.

Emma Walmsley was the first woman to hold the CEO post at the Big Pharma company.

GSK plc names new CEO as shares rise 3% and maintains a 4% dividend yield; get key insights on GSK stock's outlook and what to expect from leadership changes.

GSK Plc is “betting big on the US” and engaged in constructive talks on drug pricing with US President Donald Trump’s administration, according to Emma Walmsley, the outgoing chief executive officer ...

Emma Walmsley, who in 2017 became the first woman to lead a major pharmaceutical company, will step down from her post as CEO of GSK. She is to be succeeded by Luke Miels, who currently serves as ...